ARTICLE | Company News
Foundation Medicine, AstraZeneca deal
November 19, 2012 8:00 AM UTC
Foundation Medicine and AstraZeneca partnered to identify mutations in cancer-related tumor genes that may predict a person's response or resistance to targeted therapeutics. Foundation Medicine will ...